UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 2, 2002
Indevus Pharmaceuticals, Inc.
--------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-18728 04-3047911
--------------------------------------------------------------------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification
incorporation) Number)
One Ledgemont Center
99 Hayden Avenue
Lexington, Ma 02421-7966
--------------------------------------------------------------------------------
(Address of principal executive offices)
Registrant's telephone number, including area code:
(781-861-8444)
Interneuron Pharmaceuticals, Inc.
--------------------------------------------------------------------------------
(Former name if changed since last report.)
ITEM 5. Other Events and Regulation FD Disclosure.
On April 2, 2002, Interneuron Pharmaceuticals, Inc. changed its name to
Indevus Pharmaceuticals, Inc. Effective as of April 3, 2002, the common stock of
the Corporation began trading on the Nasdaq National Market under the trading
symbol "IDEV."
The exhibit hereto contains forward-looking statements that involve
risks and uncertainties that could cause our actual results and financial
condition to differ materially from those anticipated by the forward-looking
statements. The words "believe", "expect", "anticipate", "intend", "plan",
"estimate" or other expressions which are predictions of or indicate future
events and trends do not relate to historical matters but identify
forward-looking statements. Risks and uncertainties related to forward-looking
statements are set forth in the Company's filings under the Securities Act of
1933 and the Securities Exchange Act of 1934 and specifically under "Risk
Factors" in, or incorporated by reference into, the Company's Form
10-K for its fiscal year ended September 30, 2001 or elsewhere.
Item 7. Financial Statements and Exhibits.
(a) Financial Statements of Business Acquired: N/A
(b) Pro Forma Financial Information: N/A
(c) Exhibits:
Exhibit No. Description of Exhibit
----------- ----------------------
99.1 Press Release dated April 2, 2002
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
INDEVUS PHARMACEUTICALS, INC.
Dated: April 8, 2002 By: /s/ Glenn L. Cooper, M.D.
---------------------------------------
Glenn L. Cooper, M.D.
President, Chief Executive Officer and
Chairman
-3-